Chester County News and Community Website
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved a new frontline treatment option for adults newly diagnosed with multiple myeloma who …
FDA Clears Johnson & Johnson Myeloma Combo, Expanding Frontline Care Read More
HARRISBURG, PA — Pennsylvania is quietly pulling off what many states only promise: keeping new businesses alive long enough to thrive. New federal data shows that 56 percent of companies …
Pennsylvania’s Business Boom Defies the Odds as Survival Rates Soar Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said its experimental immune therapy nipocalimab cleared a major clinical hurdle in systemic lupus erythematosus, delivering the first positive Phase 2b …
J&J’s Lupus Breakthrough Sets the Stage for a High-Stakes Phase 3 Push Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has won U.S. Food and Drug Administration approval for RYBREVANT FASPRO, the first and only subcutaneous therapy for patients with EGFR-mutated non-small …
FDA Clears Five-Minute Lung Cancer Shot, Redefining EGFR Treatment Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved an expanded indication for AKEEGA, clearing the first FDA-approved precision medicine combination for …
FDA Clears Breakthrough Precision Combo for Aggressive Prostate Cancer Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as the first-ever treatment for adults with …
FDA Approves First Treatment for High-Risk Smoldering Multiple Myeloma Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced plans to launch the first-ever head-to-head study comparing its FcRn blocker IMAAVY™ (nipocalimab-aahu) with efgartigimod in adults living with generalized …
Johnson & Johnson Launches First Head-to-Head Study of IMAAVY in Myasthenia Gravis Read More SPRING HOUSE, PA — A new U.S. study from Johnson & Johnson (NYSE: JNJ) reveals that most people living with psoriasis — and their healthcare providers — strongly prefer effective …
New Study Finds Psoriasis Patients Favor Oral Treatments Over Injections Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced new one-year data showing that its investigational oral drug icotrokinra continues to demonstrate high rates of durable skin clearance and …
Johnson & Johnson’s Oral Psoriasis Drug Shows Strong Long-Term Results Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) released new 48-week results from its Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) as a subcutaneous induction and maintenance therapy for …
Johnson & Johnson’s TREMFYA® Shows Sustained One-Year Efficacy in Ulcerative Colitis Read More